Back to results
US 8,575,316 B2Granted
Anti-Siglec-15 antibody
AssigneeDaiichi Sankyo Company, Limited
InventorsYoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
Life of this patent
Estimating the term…
Abstract
Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
Claims22
An antibody or antigen binding fragment thereof comprising:
- a light chain sequence that comprises a light chain variable region having CDRL1, CDRL2, and CDRL3, wherein CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 47, CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 48, and CDRL3 comprises the amino acid sequence of SEQ ID NO:
- 49, and a heavy chain sequence that comprises a heavy chain variable region having CDRH1, CDRH2, and CDRH3, wherein CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 44, CDRH2 comprises the amino acid sequence selected from the group consisting of SEQ ID NO:
- 45 and SEQ ID NO:
- 97, and CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 46, wherein the antibody or antigen binding fragment thereof binds a Siglec-15 protein comprising the amino acid sequence of SEQ ID NO:
- 2 or 4,
- wherein the light chain sequence is selected from the group consisting of:
- (a) the light chain sequence comprises amino acid residues 21-238 of the amino acid sequence of SEQ ID NO:
- 69;
- (b) the light chain sequence comprises amino acid residues 21-238 of the amino acid sequence of SEQ ID NO:
- 105;
- (c) the light chain variable region comprises amino acid residues 21-133 of the amino acid sequence of SEQ ID NO:
- 69;
- and
- (d) the light chain variable region comprises amino acid residues 21-133 of the amino acid sequence of SEQ ID NO:
- 105
- or
- wherein the heavy chain sequence is selected from the group consisting of:
- (a) the heavy chain sequence comprises amino acid residues 20-466 of the amino acid sequence of SEQ ID NO:
- 101;
- (b) the heavy chain sequence comprises amino acid residues 20-466 of the amino acid sequence of SEQ ID NO:
- 99;
- (c) the heavy chain variable region comprises amino acid residues 20-140 of the amino acid sequence of SEQ ID NO:
- 101;
- and
- (d) the heavy chain variable region comprises amino acid residues 20-140 of the amino acid sequence of SEQ ID NO:
- 99.
27 more elements
Dependencies are inferred from the claim text.